Nanophotovoltaic Devices May Provide Novel Therapeutic Action

Spire Corporation (Nasdaq: SPIR), a global solar company providing turnkey solar factories and capital equipment to manufacture photovoltaic modules worldwide, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,514,725 B2 entitled "Nanophotovoltaic Devices."

This patent is for nanophotovoltaic devices formed from silicon or gallium arsenide having sizes in a range of about 50 nanometers to about 5 microns, and method of their fabrication.

Although there are a number of applications, the patent describes one application which is to inject nanophotovoltaic devices into diseased tissue, e.g., cancerous tissue, and activate these cells by the use of suitable radiation. These cells will generate electric fields in the tissue, causing a disruption of the cancerous cells.

Roger G. Little, Chairman and CEO of Spire Corporations, and co-inventor, said, “This is an extension of our solar energy technology into biotherapeutics. Functionalized nanophotovoltaic devices can go to cancerous cells in the body and when exposed to tissue penetrating light, may provide sufficient electrical energy to destroy the cells. We are continuing to exploit this technology in our research and development activities.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.